Fig. 1From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in SwitzerlandMarkov model structure, taken from National Institute of Health and Care Excellence report [23]. KEY: CF, count fingers; HM, hand motion; LP, light perception; NLP, no light perception; VA, visual acuity; VF, visual field; VI, visual impairmentBack to article page